Royalty Pharma Financing Growth Alternative Traditional Biopharmaceutical Fundraising
Facing difficult traditional equity markets, biopharmaceutical companies are increasingly turning to royalty financing. This model provides them with upfront capital in exchange for a percentage of a drug's future revenue, avoiding equity dilution. For more info: https://www.zs.com/insight...
Facing difficult traditional equity markets, biopharmaceutical companies are increasingly turning to royalty financing. This model provides them with upfront capital in exchange for a percentage of a drug's future revenue, avoiding equity dilution. For more info: https://www.zs.com/insight...
12:18 AM - Jan 16, 2026
Only people mentioned by managementconsulting in this post can reply